1. AB0455 Disease duration, but not rheumatoid factor status, impacts clinical response in adalimumab-treated rheumatoid arthritis patients with an inadequate response to standard dmard therapy: Subgroup analysis of the DE020 continuation trial. (23rd January 2014) Authors: Furst, D.E.; Weinblatt, M.E.; Kavanaugh, A.; Birbara, C.; Kupper, H.; Obermeyer, K.; Faccin, F. Journal: Annals of the rheumatic diseases Issue: Volume 71(2012)Supplement 3 Page Start: 663 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. AB0479 Patient outcomes following 10 years of treatment with adalimumab in the DE020 roll-over trial. (23rd January 2014) Authors: Weinblatt, M.E.; Furst, D.E.; Kavanaugh, A.; Faccin, F.; Kupper, H.; Obermeyer, K.; Birbara, C. Journal: Annals of the rheumatic diseases Issue: Volume 71(2012)Supplement 3 Page Start: 665 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. AB0746 Apremilast, an Oral Phosphodiesterase 4 Inhibitor, and the Impact of Baseline Weight and BMI on ACR20 and HAQ-DI Response: Pooled Results from 3 Phase 3, Randomized, Controlled Trials. (10th June 2014) Authors: Schett, G.; Mease, P.; Gladman, D.; Kavanaugh, A.; Adebajo, A.; Gomez-Reino, J.; Wollenhaupt, J.; Cutolo, M.; Lespessailles, E.; Hu, C.; Stevens, R.; Edwards, C.; Birbara, C. Journal: Annals of the rheumatic diseases Issue: Volume 73:Supplement 2(2014) Page Start: 1050 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. AB0758 Change in Weight from Baseline during the Palace Clinical Trial Program with Apremilast, an Oral Phosphodiesterase 4 Inhibitor: Pooled Results from 3 Phase 3, Randomized, Controlled Trials. (10th June 2014) Authors: Mease, P.; Gladman, D.; Kavanaugh, A.; Adebajo, A.; Gomez-Reino, J.; Wollenhaupt, J.; Schett, G.; Shah, K.; Hu, C.; Stevens, R.; Edwards, C.; Birbara, C. Journal: Annals of the rheumatic diseases Issue: Volume 73:Supplement 2(2014) Page Start: 1055 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. OP0078 Apremilast, an Oral Phosphodiesterase 4 Inhibitor, is Associated with Long-Term (52-WEEK) Improvement in Measures of Disease Activity in Patients with Psoriatic Arthritis: Results from 3 Phase 3, Randomized, Controlled Trials. (10th June 2014) Authors: Kavanaugh, A.; Cutolo, M.; Mease, P.; Gladman, D.; Adebajo, A.; Gomez-Reino, J.; Wollenhaupt, J.; Schett, G.; Lespessailles, E.; Hu, C.; Stevens, R.; Edwards, C.; Birbara, C. Journal: Annals of the rheumatic diseases Issue: Volume 73:Supplement 2(2014) Page Start: 90 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. OP0104 Apremilast, an Oral Phosphodiesterase 4 Inhibitor, in Patients with Psoriatic Arthritis Including Current Skin Involvement: Results of a Phase 3, Randomized, Controlled Trial. (23rd January 2014) Authors: Birbara, C.; Blanco, F. J.; Crowley, J. J.; Hu, C.; Stevens, R.; Edwards, C. J. Journal: Annals of the rheumatic diseases Issue: Volume 72:Supplement 3(2013) Page Start: A85 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. OP0169 Apremilast, an Oral Phosphodiesterase 4 Inhibitor, is Associated with Long-Term (104-Week) Improvements in Enthesitis and Dactylitis in Patients with Psoriatic Arthritis: Pooled Results from Three Phase 3, Randomized, Controlled Trials. (9th June 2015) Authors: Gladman, D.; Kavanaugh, A.; Adebajo, A.; Gomez-Reino, J.; Wollenhaupt, J.; Cutolo, M.; Schett, G.; Lespessailles, E.; McIlraith, M.; Hu, C.; Edwards, C.; Birbara, C.; Mease, P. Journal: Annals of the rheumatic diseases Issue: Volume 74(2015)Supplement 2 Page Start: 133 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. SAT0280 Efficacy of Apremilast, An Oral Phosphodiesterase 4 Inhibitor, on Physical Function and Pain in Patients with Psoriatic Arthritis, Including Current Skin Involvement: Results of a Phase 3, Randomized, Controlled Trial. (23rd January 2014) Authors: Birbara, C.; Blanco, F. J.; Crowley, J. J.; Hu, C.; Stevens, R.; Edwards, C. J. Journal: Annals of the rheumatic diseases Issue: Volume 72:Supplement 3(2013) Page Start: A678 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. SAT0408 Long-Term Safety and Tolerability of Apremilast, an Oral Phosphodiesterase 4 Inhibitor, in Patients with Psoriatic Arthritis: Pooled Safety Analysis of Three Phase 3, Randomized, Controlled Trials. (10th June 2014) Authors: Mease, P.J.; Kavanaugh, A.; Gladman, D.; Adebajo, A.O.; Gomez-Reino, J.J.; Wollenhaupt, J.; Cutolo, M.; Schett, G.; Lespessailles, E.; Shah, K.; Hu, C.; Stevens, R.; Edwards, C.; Birbara, C. Journal: Annals of the rheumatic diseases Issue: Volume 73:Supplement 2(2014) Page Start: 742 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
10. THU0416 Disease Activity and Safety During Long-Term (104-Week) Treatment with Apremilast, An Oral Phosphodiesterase 4 Inhibitor, in Patients with Psoriatic Arthritis: Results from a Phase III, Randomized, Controlled Trial and Open-Label Extension (Palace 3). (9th June 2015) Authors: Edwards, C.; Blanco, F.; Crowley, J.; Hu, C.; Shah, K.; Birbara, C. Journal: Annals of the rheumatic diseases Issue: Volume 74(2015)Supplement 2 Page Start: 348 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗